Peptide therapy claims on TikTok: what the science actually supports

What did @ohmedgroup actually say?

Dr. Nielsen made three core claims: that peptides have zero documented deaths or harms in medical literature, that tesamorelin reduces visceral fat and costs far less than the FDA-approved brand Egrifta (he called it "Ligerifta"), and that peptides are "just chains of amino acids" your body already uses. He also framed compounded tesamorelin as functionally identical to the brand-name drug, just cheaper. The visceral fat claim is specific and testable. The safety claim is broad and needs unpacking. The cost framing is real but legally complicated.

One factual error worth noting upfront: the FDA-approved brand name for tesamorelin is Egrifta SV, not "Ligerifta." That may be a verbal slip, but accuracy matters when you're positioning yourself as an educator with 193,000 viewers.

Does the science back this up?

On tesamorelin and visceral fat, yes, the evidence is solid. This is one of the better-supported peptide claims you'll encounter on TikTok. On the zero-harm claim, the evidence does not support that absolute framing at all.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It was studied extensively in HIV-associated lipodystrophy patients. Falutz et al. (2010, New England Journal of Medicine) showed statistically significant reductions in visceral adipose tissue compared to placebo over 26 weeks. The effect is real. The FDA approved it for that specific indication in 2010.

The safety claim is where things fall apart. Tesamorelin trials documented adverse events including fluid retention, joint pain, glucose intolerance, and potential IGF-1 elevation, which carries its own long-term questions. The claim that there is "not a single documented case" of harm from peptide therapy broadly is not a claim any honest review of the literature could make. Research-grade peptides sold outside pharmacy channels have also been associated with contamination risks (Rahnema et al., 2015, Fertility and Sterility).

What did they get wrong (or right)?

Credit where it is due: the visceral fat evidence for tesamorelin is legitimate, and the cost disparity between compounded and brand-name drugs is a real issue in American healthcare. He is not inventing the science here.

But "not a single documented case of death or harm" is false as stated. Peptides vary enormously. BPC-157 and tesamorelin are not the same category of risk as, say, research-chemical peptides bought from unregulated suppliers. Lumping them together under "peptides are incredibly safe" is the kind of oversimplification that gets people hurt. Insulin is a peptide. So is oxytocin. The amino acid chain argument does not mean much when the downstream hormonal effects are significant.

The framing that compounded tesamorelin is the "same molecule" as Egrifta SV also deserves scrutiny. FDA regulations specifically restrict this kind of equivalency claim for 503B outsourcing facilities and 503A pharmacies, because compounded drugs do not go through the same manufacturing and stability verification. That does not mean compounded tesamorelin is dangerous, but saying it is the same thing is not a claim regulators or pharmacists would endorse.

What should you actually know?

Tesamorelin has real clinical evidence behind it, more than most peptides you will see promoted on social media. But it is a prescription drug with known side effects, including glucose metabolism changes that matter if you are pre-diabetic or have insulin resistance. It also elevates IGF-1, and the long-term implications of sustained IGF-1 elevation in non-HIV patients using it off-label are not well studied.

If you are considering tesamorelin or any GHRH analog, the conversation needs to include:

• Baseline IGF-1 and fasting glucose testing
• A prescribing clinician who understands the endocrine implications, not just the fat loss outcomes
• Where your compounded peptide is coming from and whether that pharmacy is DEA/state-licensed and uses third-party testing
• The fact that off-label use means you are outside the studied population and outside FDA oversight

"Peptides aren't new, they're just early" is a catchy line. But early also means incomplete long-term safety data in healthy populations. That gap deserves more respect than a TikTok caption gives it.